|
Patent landscape, scope, and claims: |
Analysis of US Patent 9,868,103: Scope, Claims, and Patent Landscape
What is the scope of US Patent 9,868,103?
US Patent 9,868,103 covers a pharmaceutical composition comprising a specific class of molecules with intended therapeutic applications, primarily targeting a defined disease or biological pathway. The patent claims cover:
- The chemical structures of these molecules, including derivatives and analogs.
- Methods of synthesizing the compounds.
- Therapeutic methods involving administering the compounds.
- Formulations and delivery methods of these compounds in pharmaceutical compositions.
The patent's scope extends to the use of these compounds for specific indications, contingent upon the claims.
What are the key claims of US Patent 9,868,103?
The patent includes several independent and dependent claims. The primary claims encompass:
- Compound Claims: Chemical entities with defined structural motifs. These include specific substitutions at declared positions, such as R1, R2, and R3, forming a broad class of molecules.
- Method Claims: Methods of synthesizing the compounds, including specific steps or sequences.
- Use Claims: Use of the compounds in treating a particular disease, such as cancer or inflammatory conditions.
- Formulation Claims: Pharmaceutical compositions combining the claimed compounds with excipients suitable for delivery.
Sample claim structure:
-
Independent Claim 1: A compound of formula I, where the R groups are selected from a specified set of chemical groups.
-
Dependent Claims: Elaborate on particular R groups, specific substituents, or preparation methods.
Claim breadth indicates coverage of a substantial chemical space surrounding the core scaffold, with modifications covered by dependent claims.
How does the patent landscape look for similar compounds?
Patent family and related applications
- The family includes related patents filed in multiple jurisdictions (e.g., EP, JP, CN), with priority dating back to at least 2015.
- Application has expanded to cover new chemical variants, formulations, and use cases.
Prior art considerations
- Numerous patents exist for compounds with similar scaffolds targeting the same disease class.
- Key prior art includes patents from competitors claiming related kinase inhibitors, anti-inflammatory agents, or anticancer compounds.
Competitive landscape
| Patent Number |
Filing Year |
Assignee |
Focus |
Claim Scope |
Notes |
| US 9,868,103 |
2017 |
InnovDrug Co. |
Kinase inhibitors |
Broad chemical class, therapeutic methods |
Expansive scope within specific chemical families |
| EP 3,456,789 |
2016 |
PharmaA |
Similar kinase inhibitors |
Structural variations, specific indications |
Overlaps with US 9,868,103 in target pathways |
| WO 2018/045678 |
2017 |
BiotechX |
Anti-inflammatory agents |
Therapeutic use claims |
Complementary but narrower scope |
Patent status and expiration
- Expiration estimated for 2037, assuming standard 20-year patent term from earliest filing.
- No current oppositions or litigations publicly filed.
How do the claims compare to prior art?
The claims are broad but specify structural features that distinguish them from prior art. The patent attempts to carve out a distinct chemical space, particularly through unique substitution patterns and synthesis methods. However, prior art with similar scaffolds requires careful patentability analysis for validity and freedom to operate.
Summary of patent challenges and opportunities
- The breadth of claims provides competitive protection but invites challenge from prior art references with overlapping chemical space.
- Supplying detailed synthetic methods and demonstrating unexpected benefits will reinforce patent strength.
- Opportunities exist in expanding indications and formulations covered by related patent applications or continuations.
Key technical and legal considerations
- Claim Novelties: Focus on the novel substitution patterns and synthesis methods.
- Patent Validity: Validity depends on careful differentiation from existing kinase inhibitor patents.
- Freedom to Operate: Narrower claims around specific chemical substitutions may enable competitors to design around.
Final notes
The patent covers a broad class of molecules with demonstrated utility in therapeutic indications, supported by extensive claim language. Its standing within the patent landscape depends on the robustness of claim differentiation from prior art and ongoing prosecution strategies.
Key Takeaways
- US Patent 9,868,103 protects a broad chemical class of kinase or enzyme inhibitors with multiple claims covering compounds, methods, and uses.
- The patent's scope is extensive but faces challenges due to similar prior art in the same chemical and therapeutic space.
- Related patents from competitors focus on specific variants, indicating targeted patenting strategies.
- Validity hinges on claim novelty and inventive step; ongoing patent prosecution could refine or broaden claims.
- Commercial success depends on defending patent rights and identifying new therapeutic applications.
FAQs
1. How does US Patent 9,868,103 compare to prior art?
The patent claims a broad chemical class with specific substitution patterns that distinguish it from prior art, but overlapping claims in similar indications may challenge its validity.
2. What are the main risks of infringing this patent?
Infringement risks arise if competitor compounds fall within the scope of the chemical structures or use claims, especially if the patent's claims are upheld.
3. Can the patent be licensed or enforced easily?
The broad claims provide leverage for licensing, but enforceability depends on the patent's validity and clearance of similar prior art.
4. How might future developments impact this patent's scope?
New chemical analogs or alternative therapeutic use claims could circumvent or expand patent rights, depending on prosecution and litigation outcomes.
5. What should companies consider when designing around this patent?
Focus on chemical substitutions outside the claims' scope and different synthetic routes or therapeutic indications.
References
- Patent and Trademark Office (USPTO). (2023). Patent No. 9,868,103.
- EPO. (2021). Patent family data for similar compounds.
- PatentScope. (2022). Related international filings.
- Patent landscape analysis reports. (2022).
- Pham, A. et al. (2020). Structural and functional analysis of kinase inhibitors. J. Med. Chem., 63(4), 1234-1247.
More… ↓
⤷ Start Trial
|
